AbbVie Inc. (ABBV) — Business segments and KPIs
Revenue by business segment and geography for AbbVie Inc., with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| SKYRIZI | 17.56B | 30.2% |
| RINVOQ | 8.30B | 14.3% |
| H U M I R A | 4.54B | 7.8% |
| Botox Therapeutic | 3.77B | 6.5% |
| Vraylar | 3.62B | 6.2% |
| Imbruvica | 2.87B | 4.9% |
| VENCLEXTA | 2.79B | 4.8% |
| Other Products | 2.63B | 4.5% |
| Botox Cosmetic | 2.60B | 4.5% |
| MAVYRET | 1.32B | 2.3% |
| Ubrelvy | 1.27B | 2.2% |
| Other Aesthetics | 1.27B | 2.2% |
| Qulipta | 1.04B | 1.8% |
| Other Eye Care | 1.01B | 1.7% |
| Juvederm Collection | 993M | 1.7% |
| Linzess/Constella | 907M | 1.6% |
| Ozurdex | 493M | 0.8% |
| Lumigan/Ganfort | 410M | 0.7% |
| Duodopa | 381M | 0.7% |
| Other Neuroscience | 207M | 0.4% |
| Alphagan/Combigan | 197M | 0.3% |
| Revenue by region | ||
| UNITED STATES | 46.60B | 95.2% |
| Non-US | 2.36B | 4.8% |